| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
American Journal of Epidemiology Vol. 136, No. 10: 1204-1211
Copyright © 1992 by The Johns Hopkins University School of Hygiene and Public Health
research-article |
Characteristics Relating to Ovarian Cancer Risk: Collaborative Analysis of 12 US Case-Control Studies
III. Epithelial Tumors of Low Malignant Potential in White Women
1Division of Epidemtotogy, Department of Health Research and Policy, Stanford University School of Medicine Stanford, CA
2Members of the Collaborative Ovarian Cancer Group: Dr. John T. Casagrande, Department of Preventive Medicine, University of Southern California, Los Angeles, CA; Dr. Daniel Cramer, Department of Obstetrics and Gynecology, Brigham and Women's Hospital, Boston, MA; Dr. Patricia Hartge, Environmental Epidemiology Branch, National Cancer Institute, Bethesda, MD; Dr. Jennifer L Kelsey, Division of Epidemiology, Department of Health Research and Policy, Stanford University School of Medicine, Stanford, CA; Dr. Marion Lee, Department of Epidemiology, University of California, San Francisco, San Francisco, CA; Dr. Nancy C. Lee, Women's Health and Fertarty Branch, Division of Reproductive Hearth, Centers for Disease Control, Atlanta, GA; Dr. Joseph L. Lyon, Department of FamBy and Community Medfcine, The University of Utah Medical Center, Salt Lake City, UT; Dr. James R. Marshafl, Department of Social and Preventive Medicine, State University of New York at Buffalo School of Medone, Buffalo, NY; Dr. Larry McGowan, Division of Gynecologic Oncology, Department of Obstetrics and Gynecotogy, George Washington University Medical Center, Washington, DC; Dr. Philip C. Nasca, New York State Department of Health, Bureau of Cancer Epidemiology, School of Public Health, Department of Epidemiology, Albany, NY; Dr. Ratph S.Paffenbarger, Jr., Division of Epidemiology, Department of Health Research and Policy, Stanford University School of Medicine, Stanford, CA; Dr. Lynn Rosenberg, Stone Epidemiology Unit, School of Public Health, Boston University School of Medicine, Brookline, MA; and Dr. Noel S. Weiss, Department of Epidemiology, School of Public Health and Community Medkane, University of Washington, Seattle, WA. Project Consultant: Dr. Genrose D. Copley, Extramural Programs, Division of Cancer Etiology, National Cancer Institute, Bethesda, MD.
Reprint requests to Dr. Alice S. Whittemore, Stanford University School of Medicine, Department of Health Research and Policy, HRP Modular no. 2, Stanford, CA 94305–5092.
Epithelial ovarian neoplasms of low malignant potential, also called borderline ovarian tumors, have various features of malignancy, but they do not invade the ovarian stroma. Women with these tumors usually are younger when diagnosed and have better prognoses than do women with invasive tumors. There have been few epidemiologic studies of borderline tumors, and it is unclear whether there are etiologic differences between the two types of tumor behavior. Combined data from nine case-control studies, conducted from 1974 to 1986 and representing 327 white women with tumors of low malignant potential and 4, 144 white controls, were used to evaluate the relation between these tumors and personal characteristics related to invasive ovarian cancer. The risk profile for tumors of low malignant potential was found to be similar to that for invasive tumors, with two exceptions: Compared with that of invasive tumors, risk of borderline tumors was less clearly reduced among women who had used oral contraceptives and more clearly elevated among women with a history of Infertility. Am J Epidemiol 1992; 136: 1204–11
estrogens; fertility agents; female; infertility; lactation; pregnancy
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  C. Basille, F. Olivennes, J. Le Calvez, N. Beron-Gaillard, G. Meduri, C. Lhomme, P. Duvillard, J. Benard, and P. Morice Impact of gonadotrophins and steroid hormones on tumour cells derived from borderline ovarian tumours Hum. Reprod., December 1, 2006; 21(12): 3241 - 3245. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J. Jordan, P. M. Webb, and A. C. Green Height, Age at Menarche, and Risk of Epithelial Ovarian Cancer Cancer Epidemiol. Biomarkers Prev., August 1, 2005; 14(8): 2045 - 2048. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Fauvet, J. Boccara, C. Dufournet, C. Poncelet, and E. Darai Laparoscopic management of borderline ovarian tumors: results of a French multicenter study Ann. Onc., March 1, 2005; 16(3): 403 - 410. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Lukanova and R. Kaaks Endogenous Hormones and Ovarian Cancer: Epidemiology and Current Hypotheses Cancer Epidemiol. Biomarkers Prev., January 1, 2005; 14(1): 98 - 107. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Rossing, M.-T. C. Tang, E. W. Flagg, L. K. Weiss, and K. G. Wicklund A Case-Control Study of Ovarian Cancer in Relation to Infertility and the Use of Ovulation-inducing Drugs Am. J. Epidemiol., December 1, 2004; 160(11): 1070 - 1078. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. A. Brinton, E. J. Lamb, K. S. Moghissi, B. Scoccia, M. D. Althuis, J. E. Mabie, and C. L. Westhoff Ovarian Cancer Risk After the Use of Ovulation-Stimulating Drugs Obstet. Gynecol., June 1, 2004; 103(6): 1194 - 1203. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K.-H. Tung, M. T. Goodman, A. H. Wu, K. McDuffie, L. R. Wilkens, L. N. Kolonel, A. M. Y. Nomura, K. Y. Terada, M. E. Carney, and L. H. Sobin Reproductive Factors and Epithelial Ovarian Cancer Risk by Histologic Type:A Multiethnic Case-Control Study Am. J. Epidemiol., October 1, 2003; 158(7): 629 - 638. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Klip, F. E. van Leeuwen, R. Schats, C.W. Burger, and for the OMEGA project group Risk of benign gynaecological diseases and hormonal disorders according to responsiveness to ovarian stimulation in IVF: a follow-up study of 8714 women Hum. Reprod., September 1, 2003; 18(9): 1951 - 1958. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. T. Goodman and K.-H. Tung Alcohol Consumption and the Risk of Borderline and Invasive Ovarian Cancer Obstet. Gynecol., June 1, 2003; 101(6): 1221 - 1228. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. J. Schouten, R. A. Goldbohm, and P. A. van den Brandt Height, Weight, Weight Change, and Ovarian Cancer Risk in the Netherlands Cohort Study on Diet and Cancer Am. J. Epidemiol., March 1, 2003; 157(5): 424 - 433. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. M. Fairfield, W. C. Willett, B. A. Rosner, J. E. Manson, F. E. Speizer, and S. E. Hankinson Obesity, Weight Gain, and Ovarian Cancer Obstet. Gynecol., August 1, 2002; 100(2): 288 - 296. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Syed, G. Ulinski, S. C. Mok, G. K. Yiu, and S.-M. Ho Expression of Gonadotropin Receptor and Growth Responses to Key Reproductive Hormones in Normal and Malignant Human Ovarian Surface Epithelial Cells Cancer Res., September 1, 2001; 61(18): 6768 - 6776. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Rodriguez, A. V. Patel, E. E. Calle, E. J. Jacob, and M. J. Thun Estrogen Replacement Therapy and Ovarian Cancer Mortality in a Large Prospective Study of US Women JAMA, March 21, 2001; 285(11): 1460 - 1465. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Cosman and R. Lindsay Selective Estrogen Receptor Modulators: Clinical Spectrum Endocr. Rev., June 1, 1999; 20(3): 418 - 434. [Abstract] [Full Text]
|
|
|
|
 |
|
 G. Del Priore, K. Robischon, W. R. Phipps, R. Kurman, E. E. Wallach, H. A. Zacur, S. Shapiro, M. A. Rossing, J. R. Daling, N. S. Weiss, et al. Risk of Ovarian Cancer after Treatment for Infertility N. Engl. J. Med., May 11, 1995; 332(19): 1300 - 1302. [Full Text]
|
|
|
|
|
|
M. A. Rossing, J. R. Daling, N. S. Weiss, D. E. Moore, and S. G. Self Ovarian Tumors in a Cohort of Infertile Women N. Engl. J. Med., September 22, 1994; 331(12): 771 - 776. [Abstract] [Full Text]
|
|
|
|
|
|
A. S. Whittemore The Risk of Ovarian Cancer after Treatment for Infertility N. Engl. J. Med., September 22, 1994; 331(12): 805 - 806. [Full Text]
|
|